Abstract
Background:
C-C chemokine receptor 5
Abstract
Background:
C-C chemokine receptor 5 (CCR5) is implicated in tumor progression, immune modulation, and metastatic behavior in colorectal cancer. Leronlimab (LRM) is a humanized monoclonal antibody targeting CCR5 already showing promising activity in patients with metastatic triple-negative breast cancer. The open-label phase-2 CLOVER (CCR5-targeting leronlimab with Oral chemotherapy and VEGF-inhibitor Enriched Regimen) trial evaluates the efficacy and safety of LRM in combination with TAS-102 plus bevacizumab (BEV).
Methods:
CLOVER (NCT06699836) plans to enroll up to 60 patients with refractory mCRC eligible for TAS-102 plus BEV and with CCR5-positive tumors by IHC. LRM will be administered weekly at 350 mg (cohort 1) or 700 mg (cohort 2) subcutaneously, with TAS-102 plus BEV at standard doses. Cohort 2 will be initiated if no LRM dose-limiting toxicities (DLTs) are seen in cohort 1. Primary objectives include safety and objective response rate per RECIST v1.1 criteria. Other evaluations include ctDNA kinetics, and PD-L1 expression on circulating tumor cells (CTCs) and cancer associated macrophage-like cells (CAMLs).
Results:
All pre-screened patients with evaluable archival samples met prespecified criteria for CCR5 expression (Table). As of abstract drafting 23/37 (62.2%) screened patients have been enrolled. No LRM-related DLTs have been observed at 350 mg and 700 mg LRM dosing has commenced. Among six patients with evaluable centrally assessed images all patients thus far have stable disease and remain on study treatment. All patients with available data have shown a numerical reduction in ctDNA by as early as Week 2 (Table) either paralleling or preceding clinical/biomarker improvement (CEA, CA-19-9, liver function tests). Increases in PD-L1 have been observed in CTCs and CAMLs (Table).
Conclusions:
In the CLOVER trial LRM in combination with TAS-102 plus BEV has been well tolerated with no LRM-related DLTs. Rapid declines in ctDNA have been observed along with stable objective responses, with most patients having baseline liver metastases and RAS-mutant. At the time of abstract submission approximately half of the target number of patients have been enrolled and at the time of presentation the trial is expected to be fully or close to fully enrolled. Observations of increases in PD-L1 on CTCs and/or CAMLs are hypothesis-generating and support investigation of immune checkpoint inhibitor strategies for patients who progress.
Parameter
Result
CCR5 expression for all pre-screened patients: n/N (%)
64/64 (100%)
Age (N=23): median (range)
51 years (31-76 years)
Weight (N=23): median (range)
73.8 kg (46.2-112.9)
Sex (N=23)
Male n=15; female n=8
Change in tumor size: median (range)
-10.2% (+12.5 to -28.4%)
Change in ctDNA (N=11): median (range)
-85% (-9%-99%)
PD-L1 increase in CAMLs/CTCs by Week 5 (N=17)
12/17 (70.6%)
Disclaimer
This material on this page is ©2026 American Society of Clinical Oncology, all rights reserved. Licensing
10
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Meta Bets on Green Steel's Future Out of left field, we've got Meta cozying up to Stegra in a pretty big way. They just inked a deal for environmental attribute certificates (EACs) that could shake up the steel industry. These two players are coming together to embrace something that's still piping hot and fresh off the press: sustainable steel. Stegra, still in its...
Continue Reading
Huntsman Corporation Delivers Dividend Update So, here's the lowdown from Huntsman Corporation coming at us on a rather sleepy November morning in 2026. They've announced their fourth quarter dividend—a neat $0.0875 per share. Now, this isn’t exactly hitting us like a seismic shockwave, but every little drip counts when you're invested in NYSE:HUN, which is exactly...
Continue Reading
Unearthing the Heartbeat of a Bygone Era Picture this: a bustling fairground teeming with the simple pleasures of bygone days, where the echoes of tradition mingle with the excitement of competition. This is the vivid tapestry that Dr. Paul J. Carr paints in his latest historical exposé, Farming, Community, and the Legacy of The Suffolk County Agricultural Society's...
Continue Reading
Thriving in a Complex Energy World You know, for Frontera Energy Corporation, it's not just about tossing around tanker loads of cash—it’s about working those numbers into something real. Their Q3 2026 gives us a peep into how they’re keeping the hot iron pressed against opportunity. With a net income of $11.7 million and adjusted EBITDA jumping 16% to top $34.8...
Continue Reading
The Tumbling Honeywell Aerospace Saga Some days, stocks have you feeling like a cat stranded in a tree, and right now, Honeywell Aerospace (NASDAQ:HONA) is very much that cat—with branches breaking beneath it. Investors have been tossed into the fray after the company’s stock nosedived over 23% following ominous earnings and legal revelations. It's a market story...
Continue Reading
Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...
Continue Reading
UFORCE Punches Up with a Solid $700M Funding Round If there's one thing that's become crystal clear, it's that defense tech needs to be faster, cheaper, and smarter. Well, UFORCE just pumped up the volume with a whopping $700 million in fresh capital, pegged at a $6 billion valuation. You bet that's a loud statement in today's tense geopolitical climate. A Global Roll...
Continue Reading
Broad Collaborations in Life Sciences Seems like BioMap is on a mission to shake things up. The folks at the International Bio-Computing Innovation Summit 2026 in Hong Kong sure didn’t hold back on the announcements—seriously, eleven partnerships? These collaborations stretch across drug research, traditional Chinese medicine, agriculture, and even an international...
Continue Reading
The Dawn of the Agent Web Well, here we are, standing at the cusp of a new digital frontier, folks. This ain't just another buzzword parade; this is the Open Agentic Web Challenge, courting developers with a $13K carrot to craft an interoperable playground for AI agents. Big names like Cognizant AI Lab, MIT Media Lab, and others are leading the charge. No small-time...
Continue Reading
Oxford Computer Group Strikes Again Another day, another nod from the big boys at Microsoft, eh? Oxford Computer Group, now part of MajorKey Technologies, hasn't just found themselves in the mix—they're standing tall as a finalist for not one but two significant categories in the 2026 Microsoft Partner of the Year Awards: Secure Access and Defense and Intelligence. You...
Continue Reading
Top 5 Most Recently Viewed Articles
Critical Metals Corp Announces New Infill Diamond Drilling Program Critical Metals Corp. (Nasdaq: CRML), a prominent player in critical minerals mining, has made a substantial commitment to advancing its Tanbreez Project through a newly signed diamond drilling contract valued at $2 million. This significant endeavor is set to take place in Greenland with the esteemed...
Continue Reading
N-iX Earns Recognition from Everest Group N-iX, a leading global software solutions and engineering services provider, has received notable recognition from the Everest Group in its assessment of software product engineering services for 2024. This prestigious acknowledgment highlights N-iX's outstanding contributions and capabilities within the industry. Understanding...
Continue Reading
Turning Career Challenges into Leadership Growth In today's fast-evolving job market, many professionals face what is often called "career grief"—the emotional strain caused by uncertainties and job changes. Brittany N. Cole, a leading voice and inclusive workforce strategist, has crafted effective strategies to inspire individuals to thrive in their careers. In her...
Continue Reading
Transforming Transportation: The Rise of Mobility-as-a-Service The mobility-as-a-service (MaaS) market is poised for significant transformation, with an estimated growth of USD 639.92 billion from 2024 to 2028. This growth represents a compound annual growth rate (CAGR) of almost 35.15% during the specified period, driven largely by advancements in artificial intelligence...
Continue Reading
Pomerantz Law Firm's Investigation into Ardent Health, Inc. Pomerantz LLP is actively investigating claims on behalf of investors regarding Ardent Health, Inc. This investigation stems from concerns that certain officers and directors of Ardent may have engaged in illegal business practices and securities fraud, which could affect investors significantly. Concerns About...
Continue Reading